ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

LIAN LianBio

0.319
0.00 (0.00%)
17 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
LianBio LIAN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 0.319 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.319 0.319
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/3/202406:51EDGAR2Form 25 - Notification of the removal from listing and..
28/2/202406:00GLOBELianBio Announces Voluntarily Delisting from Nasdaq
20/2/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202406:04EDGAR2Form 8-K - Current report
13/2/202406:00GLOBELianBio Announces Completion of Strategic Review
08/1/202405:13EDGAR2Form 144 - Report of proposed sale of securities
29/12/202306:56EDGAR2Form 144 - Report of proposed sale of securities
26/12/202315:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/12/202315:07EDGAR2Form 8-K - Current report
26/12/202313:40APSBiotech Finds Success Following Holiday Weekend
26/12/202301:00GLOBELianBio Enters into Agreement Assigning its Rights for..
20/12/202307:05EDGAR2Form 8-K - Current report
20/12/202307:00GLOBELianBio Announces Departure of Chief Financial Officer
19/12/202315:26EDGAR2Form 8-K - Current report
19/12/202315:05GLOBELianBio Announces Departure of Chief Executive Officer
06/12/202315:23EDGAR2Form 8-K - Current report
06/12/202315:05GLOBELianBio’s Board of Directors Unanimously Determines not to..
01/12/202315:16EDGAR2Form 8-K - Current report
01/12/202315:05GLOBELianBio Confirms Receipt of Unsolicited Proposal from..
13/11/202315:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:17EDGAR2Form 8-K - Current report
13/11/202315:05GLOBELianBio Reports Third Quarter 2023 Financial Results and..
30/10/202315:16EDGAR2Form 8-K - Current report
30/10/202315:05GLOBELianBio Announces Topline Results from Phase 3 LIBRA Trial..
25/10/202315:05GLOBELianBio Announces Presentation of Data from Phase 2a Study..
24/10/202309:25APSBiotech Shares Soar Premarket
24/10/202308:22DJNLianBio Shares Soar Premarket on Strategic Review, End of..
24/10/202305:59GLOBELianBio Enters into Agreement with Bristol Myers Squibb for..
28/8/202315:05GLOBELianBio Announces Results from Phase 3 EXPLORER-CN Trial of..
14/8/202315:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202315:11EDGAR2Form 8-K - Current report
14/8/202315:05GLOBELianBio Reports Second Quarter 2023 Financial Results and..
03/8/202315:05GLOBELianBio Announces First Patient Treated in Phase 1 Trial of..
26/7/202307:30GLOBELianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA..
18/7/202307:00GLOBELianBio Partner NANOBIOTIX Enters into License Agreement..
17/7/202305:00GLOBELianBio Announces Phase 3 EXPLORER-CN Data Accepted for..
12/7/202307:00GLOBELianBio Announces Clinical Supply Agreement with AstraZeneca..
26/6/202307:00GLOBELianBio Announces Marketing Approval of CAMZYOS®..